Abeona

Abeona Therapeutics Reports Second Quarter Financial Results

Retrieved on: 
Wednesday, July 28, 2021
Abeona

NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the second quarter 2021 and recent business progress.

Key Points: 
  • ET
    NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the second quarter 2021 and recent business progress.
  • The second quarter was a highly effective and productive quarter for Abeona, and we remain committed to delivering operational excellence and bringing our gene therapies to patients with no approved treatments, said Michael Amoroso, Chief Executive Officer of Abeona.
  • Total general and administrative (G&A) spending was $5.5 million in the second quarter of 2021, down from the $6.6 million spent in the first quarter of 2021.
  • ET, to discuss its second quarter 2021 financial results and business update.

Abeona Therapeutics Issues Letter to Stockholders

Retrieved on: 
Wednesday, May 26, 2021
Genodermatoses, Rare diseases, Collagen disease, Epidermolysis bullosa dystrophica, Health, Clinical medicine, Epidermolysis bullosa, Abeona, Sanfilippo syndrome, Branches of biology

NEW YORK and CLEVELAND, May 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to stockholders in conjunction with the 2021 Abeona Therapeutics Annual Meeting of Stockholders to be held today, May 26, 2021:

Key Points: 
  • NEW YORK and CLEVELAND, May 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to stockholders in conjunction with the 2021 Abeona Therapeutics Annual Meeting of Stockholders to be held today, May 26, 2021:
    We at Abeona remain committed to bringing urgently needed treatments to patients with recessive dystrophic epidermolysis bullosa (RDEB), and Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB, respectively).
  • Our strengthened board and management team represent a group of highly qualified and diverse executives who bring fresh perspectives, relevant operational expertise with life sciences companies and leadership experience to Abeona.
  • EB-101 has already shown durable healing of large, chronic RDEB wounds and associated pain reduction in a phase 1/2 clinical trial.
  • In conclusion, I would like to thank our stockholders for supporting our efforts and sharing in our lofty goals.

Abeona Therapeutics Reports Third Quarter Financial Results

Retrieved on: 
Monday, November 9, 2020
Jefferies Group, NASDAQ, Abeona, Finance, Ships, New York City

NEW YORK and CLEVELAND, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the third quarter 2020 and recent business progress.

Key Points: 
  • NEW YORK and CLEVELAND, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the third quarter 2020 and recent business progress.
  • In October 2020, Michael Amoroso, Senior Vice President and Chief Commercial Officer at Abeona, was promoted to Chief Operating Officer.
  • Abeona continues to work with Jefferies LLC as its financial advisor in the review of strategic options focused on advancing the Companys mission and maximizing stakeholder value.
  • ET, to discuss its third quarter 2020 financial results and business update.

Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer

Retrieved on: 
Tuesday, October 27, 2020
Amoroso, Abeona

NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior Vice President and Chief Commercial Officer at Abeona, has been promoted to Chief Operating Officer and will serve as the Companys principal executive and operating officer, effective November 1, 2020.

Key Points: 
  • NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior Vice President and Chief Commercial Officer at Abeona, has been promoted to Chief Operating Officer and will serve as the Companys principal executive and operating officer, effective November 1, 2020.
  • Mr. Amoroso stated, Abeona has a significant foundation in place with a compelling vision, great people, deep science and a robust pipeline of advanced and early stage programs.
  • Mr. Amoroso has served as Senior Vice President and Chief Commercial Officer of Abeona since July 2020.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.

Abeona Therapeutics Announces Leadership and Board Transitions

Retrieved on: 
Monday, September 28, 2020
Abeona, Ships

NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive leadership and Board of Directors.

Key Points: 
  • NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive leadership and Board of Directors.
  • On September 27, 2020, Brian Pereira, M.D., Stefano Buono, Stephen B. Howell, M.D., George Migausky and Shawn Tomasello each announced that they had stepped down from the Board, effective immediately.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.
  • Investor Contact: Greg Gin VP, Investor Relations Abeona Therapeutics +1 (646) 813-4709 [email protected] Media Contact: Scott Santiamo Director, Corporate Communications Abeona Therapeutics +1 (718) 344-5843 [email protected]

Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors

Retrieved on: 
Tuesday, April 21, 2020
Abeona, Ships

NEW YORK and CLEVELAND, April 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian Pereira, M.D.

Key Points: 
  • NEW YORK and CLEVELAND, April 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian Pereira, M.D.
  • and Shawn Tomasello, M.B.A. as Executive Chairman and Independent Board Member, respectively.
  • On behalf of the Board, I am pleased to welcome Brian and Shawn, and look forward to collaborating with them as we guide Abeona to success, said Steven H. Rouhandeh, former Executive Chairman and current Director.
  • Dr. Pereira continued, On behalf of the Board and all Abeona employees, I am grateful to Steve, Dick, and Mark for their service and dedication to the company.

Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic

Retrieved on: 
Friday, March 27, 2020
Health, Articles, Drug discovery, Pharmaceutical industry, Biotechnology, Abeona, Therapy, Biopharmaceutical, Clinical trial

We at Abeona are thankful for their sacrifices and efforts, and stand behind these healthcare institutions whose resources are focused on the greater good.

Key Points: 
  • We at Abeona are thankful for their sacrifices and efforts, and stand behind these healthcare institutions whose resources are focused on the greater good.
  • Abeona is fully focused on getting through the pandemic by working closely with our clinical trial sites to ensure that patient safety remains paramount.
  • Abeona is about great Science and great People, and its important we continue to do everything we can to preserve both.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.

ABEO NOTICE: Pawar Law Group Reminds Investors of JANUARY 2 Deadline in Securities Class Action Lawsuit Against Abeona Therapeutics Inc.– ABEO

Retrieved on: 
Wednesday, December 18, 2019
Civil law, Class action, Abeona, Plaintiff

NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) from May 31, 2018 through September 23, 2019, inclusive (the Class Period).

Key Points: 
  • NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) from May 31, 2018 through September 23, 2019, inclusive (the Class Period).
  • The lawsuit seeks to recover damages for Abeona Therapeutics Inc. investors under the federal securities laws.
  • If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2020.
  • To express an interest in the class action, go http://pawarlawgroup.com/cases/abeona-therapeutics-inc/ or call Vik Pawar, Esq.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Abeona Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – ABEO

Retrieved on: 
Tuesday, December 17, 2019
Life sciences, Articles, Biotechnology, Abraham Pomerantz, Pomerantz, Biopharmaceutical, Abeona

NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ:ABEO) and certain of its officers.

Key Points: 
  • NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ:ABEO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Abeona is a clinical-stage biopharmaceutical company that purports to develop cell and gene therapies for life-threatening rare genetic diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Abeona Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – ABEO  

Retrieved on: 
Thursday, December 12, 2019
Life sciences, Articles, Biotechnology, Abraham Pomerantz, Pomerantz, Biopharmaceutical, Abeona

NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ:ABEO) and certain of its officers.

Key Points: 
  • NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ:ABEO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Abeona is a clinical-stage biopharmaceutical company that purports to develop cell and gene therapies for life-threatening rare genetic diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.